Johannesburg - Shares of South Africa's Aspen Pharmacare rise 3 percent to 262.13 rand after earlier hitting a lifetime high, as the stock extends gains from Wednesday when the drugmaker posted strong full-year earnings and detailed plans to expand into Russia and Eastern Europe.
The generic drugs maker says the purchase of manufacturing units from US firm Merck and GlaxoSmithKline will pave the way for its expansion to Russia, other former Soviet republics, and across Europe, as well as extend its influence in Latin America and Asia.
Aspen is the top performer on Johannesburg's blue-chip Top-40 index for the second straight session.
Shares of the company rose more than 4 percent on Wednesday. - Reuters